Valuation: Solid Biosciences Inc.

Market Cap 858M 752M 696M 640M 1.21B 82.78B 1.23B 8.32B 3.26B 40.51B 3.22B 3.15B 140B P/E 2026 *
-4.5x
P/E 2027 * -4.48x
Enterprise Value 633M 555M 513M 472M 890M 61.05B 904M 6.13B 2.4B 29.87B 2.38B 2.33B 103B EV / Sales 2026 *
-
EV / Sales 2027 * 62.1x
Free-Float
87.17%
Yield 2026 *
-
Yield 2027 * -
1 day-1.32%
1 week-11.42%
Current month-13.81%
1 month+3.73%
3 months+1.41%
6 months+53.20%
Current year+52.66%
1 week 8.48
Extreme 8.48
9.94
1 month 8.1
Extreme 8.105
11.45
Current year 4.92
Extreme 4.92
11.45
1 year 3.79
Extreme 3.79
11.45
3 years 1.81
Extreme 1.81
15.05
5 years 1.81
Extreme 1.81
51.3
10 years 1.81
Extreme 1.81
822.6
Manager TitleAgeSince
Chief Executive Officer 55 2022-12-01
Corporate Officer/Principal - 2014-08-31
Director of Finance/CFO 48 2023-01-08
Director TitleAgeSince
Director/Board Member 52 2013-02-28
Director/Board Member 60 2015-10-31
Director/Board Member 46 2015-10-31
Date Insider Type Main position Quantity % Market Cap.
7/2/26 Fiscal year

Chairman

6,880 0.0070%
6/22/26
RA Capital Management LP
OtherCompany 20,214,538 20.5329%
6/10/26 Free

Director

77,500 0.0787%
Change 5-day change 1-year change 3-year change Capi.($)
-1.20%-11.42%+35.16%+81.65% 858M
+0.21%-0.79%+56.02%+57.39% 53.83B
+5.37%+0.75%+50.39%+83.03% 52.1B
+0.29%-0.22%+5.95%+411.48% 23.48B
+0.75%+2.46%-15.26%-14.32% 23.13B
+3.46%+0.79%+34.01%-4.47% 19.36B
-1.18%-2.97%+32.73%-33.30% 17.56B
-1.67%-8.56%+163.95%+284.69% 15.2B
+3.62%-2.42%+29.70%+663.64% 14.83B
+0.72%+0.60%+27.37%+183.72% 14.06B
Average +1.03%-3.82%+42.00%+171.35% 23.44B
Weighted average by Cap. +1.70%-2.40%+42.70%+140.33%

Financials

2026 *2027 *
Net sales - 11.08M 9.72M 8.98M 8.26M 15.58M 1.07B 15.83M 107M 42.09M 523M 41.62M 40.71M 1.8B
Net income -232M -203M -188M -173M -326M -22.33B -331M -2.24B -879M -10.93B -870M -851M -37.64B -255M -223M -207M -190M -358M -24.59B -364M -2.47B -968M -12.03B -957M -936M -41.45B
Net Debt -225M -198M -183M -168M -317M -21.73B -322M -2.18B -856M -10.63B -846M -828M -36.63B -170M -149M -138M -127M -240M -16.44B -244M -1.65B -647M -8.04B -640M -626M -27.72B
Logo Solid Biosciences Inc.
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Employees
121
Date Price Change Volume
26-07-20 US$8.600 -1.38% 340,214
26-07-17 US$8.720 -3.65% 1,493,249
26-07-16 US$9.050 -5.93% 1,014,838
26-07-15 US$9.620 -0.10% 951,058
26-07-14 US$9.630 -0.93% 907,961
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
8.720USD
Average target price
17.50USD
Spread / Average Target
+100.69%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SLDB Stock